U.S. flag

An official website of the United States government

GTR Home > Tests > Fanconi Anemia via the RAD51C/FANCO Gene

Indication

This is a clinical test intended for Help: Diagnosis, Screening, Pre-symptomatic, Risk Assessment, Mutation Confirmation

Clinical summary

Help

Imported from GeneReviews

Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.

Clinical features

Help

Imported from Human Phenotype Ontology (HPO)

  • Anal atresia
  • Cryptorchidism
  • Abnormal heart morphology
  • Hydronephrosis
  • Short stature
  • Chromosome breakage
  • Short thumb
  • Rectal atresia
  • Hypoplasia of the radius
  • Small thenar eminence
  • External genital hypoplasia
  • Proximal placement of thumb
  • Stage 5 chronic kidney disease
  • Absent thumb
  • Renal cyst
Show all

Conditions tested

Target population

Help

Patients with clinical features of FA and positive chromosome breakage tests, patients with a family history of FA or cancer, and patients who develop aplastic anemia at any age. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in RAD51C.

Citations

Not provided

Clinical validity

Help

Not provided

Clinical utility

Help

Not provided

Practice guidelines

  • FARF, 2020
    Fanconi Anemia Clinical Care Guidelines, Fifth Edition.
  • FARF, 2008
    Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008 (See 2020 Update)

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.